Evidence map›Paper›PMID 30510572›Full record

ArticleGastroenterology research and practice2018

Repeated Autologous Bone Marrow Transfusion through Portal Vein for Treating Decompensated Liver Cirrhosis after Splenectomy.

Weiwei Zhang, Mujian Teng, Baochi Liu, Qiling Liu, Xin Liu, Yanhui Si, Lei Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology research and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Weiwei ZhangDepartment of Hepatobiliary Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China.ORCID 0000-0001-5952-4173
Mujian TengDepartment of Hepatobiliary Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China.ORCID 0000-0003-0841-0576
Baochi LiuDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qiling LiuDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xin LiuDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yanhui SiDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Lei LiDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study is aimed at examining the impact of repeated intraportal autologous bone marrow transfusion (ABMT) in patients with decompensated liver cirrhosis after splenectomy.

methodsA total of 25 patients with decompensated liver cirrhosis undergoing splenectomy were divided into ABMT and control groups. The portal vein was cannulated intraoperatively using Celsite Implantofix through the right gastroomental vein. Both groups were given a routine medical treatment. Then, 18 mL of autologous bone marrow was transfused through the port in the patients of the ABMT group 1 week, 1 month, and 3 months after laminectomy, while nothing was given to the control group. All patients were monitored for adverse events. Liver function tests, including serum albumin (ALB), alanine aminotransferase (ALT), total bilirubin (TB), prothrombin activity (PTA), cholinesterase (CHE),

resultsSignificant improvements in ALB, ALT, and CHE levels and decreased LSM were observed in the ABMT group compared with those in the control group (

conclusionsRepeated intraportal ABMT was clinically safe, and liver function of patients significantly improved. Therefore, this therapy has the potential to treat patients with decompensated liver cirrhosis after splenectomy. This trial was registered with the identification number of ChiCTR-ONC-17012592.

Identifiers

PMID30510572
PMCPMC6231388
OpenAlexW2898989732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.